45,748 Shares in OptimizeRx Co. (NASDAQ:OPRX) Purchased by Marshall Wace LLP

Marshall Wace LLP purchased a new stake in OptimizeRx Co. (NASDAQ:OPRX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 45,748 shares of the company’s stock, valued at approximately $457,000. Marshall Wace LLP owned approximately 0.25% of OptimizeRx as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. First Light Asset Management LLC increased its position in shares of OptimizeRx by 0.6% in the first quarter. First Light Asset Management LLC now owns 1,737,584 shares of the company’s stock worth $21,112,000 after purchasing an additional 10,286 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock worth $12,482,000 after buying an additional 6,291 shares during the last quarter. AWM Investment Company Inc. raised its position in shares of OptimizeRx by 4.0% during the 1st quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock valued at $10,364,000 after buying an additional 33,000 shares in the last quarter. Blair William & Co. IL lifted its holdings in shares of OptimizeRx by 5.6% during the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock worth $9,508,000 after acquiring an additional 41,469 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its position in OptimizeRx by 23.5% in the second quarter. Rice Hall James & Associates LLC now owns 496,135 shares of the company’s stock worth $4,961,000 after acquiring an additional 94,253 shares in the last quarter. Institutional investors own 76.47% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on OPRX. B. Riley assumed coverage on OptimizeRx in a research note on Thursday, July 25th. They set a “buy” rating and a $18.50 price target for the company. Royal Bank of Canada dropped their target price on OptimizeRx from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. JMP Securities reiterated a “market outperform” rating and set a $16.00 price target on shares of OptimizeRx in a research report on Friday, June 21st. Finally, Barclays decreased their price target on shares of OptimizeRx from $15.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and an average target price of $14.50.

OptimizeRx Stock Up 2.8 %

Shares of NASDAQ OPRX opened at $6.57 on Friday. The company has a market cap of $120.03 million, a price-to-earnings ratio of -6.44 and a beta of 1.27. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.27. The firm’s fifty day moving average is $7.95 and its 200 day moving average is $9.87. OptimizeRx Co. has a 52 week low of $6.30 and a 52 week high of $16.65.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The firm had revenue of $18.81 million for the quarter, compared to analysts’ expectations of $20.47 million. OptimizeRx had a negative net margin of 21.53% and a negative return on equity of 5.97%. On average, equities research analysts expect that OptimizeRx Co. will post -0.33 earnings per share for the current year.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.